Inflation is raging, but these 16 companies have pricing power
Amgen — The biotech stock ticked up 0.6% following an upgrade to outperform from Leerink Partners, with analyst David Risinger highlighting long-term revenue potential of $19.3 billion. DaVita, Novo Nordisk — Shares of the dialysis services provider sank 15% on the news of Ozempic's effectiveness